Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyradiotherapyDiseaseVulvar CarcinomaSubgroupICD10C51.9MeSHVulvaSequenceChemotherapyChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesium sulfatePotassium chlorideNo. Substances6Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)InfectionsLeukopeniaNeutropeniaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorMoore DHDiseaseVulvakarzinom, T3/T4, N0-3, M0, für eine radikale Vulvektomie nicht geeignet, keine VortherapieOriginGynecologic Oncology of Indiana, Indianapolis, USA, GOG studyProtocols in Revision 1 protocol foundProtocols under revision.Cisplatin 40 / Radiatio, Vulvar Carcinoma (PID2116)